Trial Profile
Post-authorisation Safety Study to Assess the Risk of Urinary Tract Malignancies in Relation to Empagliflozin Exposure in Patients With Type 2 Diabetes: a Multi-database European Study
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 26 Jun 2023
Price :
$35
*
At a glance
- Drugs Empagliflozin (Primary) ; Dipeptidyl peptidase 4 inhibitors; Sodium-glucose transporter 2 inhibitors
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Jun 2023 Planned End Date changed from 1 Jun 2023 to 29 Mar 2024.
- 20 Jun 2023 Planned primary completion date changed from 1 Jun 2023 to 29 Mar 2024.
- 07 Oct 2022 Planned End Date changed from 30 Sep 2022 to 1 Jun 2023.